OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling

American Journal of Cancer Research

Volumn 5, Issue 5, 2015, Pages 1635-1648

  Li, Chunhong ^a   Tang, Liping ^a   Zhao, Lijuan ^a   Li, Lili ^b   Xiao, Qian ^a   Luo, Xinrong ^a   Peng, Weiyan ^a   Ren, Guosheng ^a   Tao, Qian ^a,b   Xiang, Tingxiu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Methylation; OPCML; Tumor suppressor

Indexed keywords

EID: 85006228025     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Tang YR, Wang P, Yin R, Ge JX, Wang GP and Lin L. Five-year follow-up of 263 cases of functional bowel disorder. World J Gastroenterol 2013; 19: 1466-1471.
3. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabunciyan S and Feinberg AP. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41: 178-186.
4. Yin X, Xiang T, Li L, Su X, Shu X, Luo X, Huang J, Yuan Y, Peng W, Oberst M, Kelly K, Ren G and Tao Q. DACT1, an antagonist to Wnt/beta-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Res 2013; 15: R23.
5. Hackanson B and Daskalakis M. Decitabine. Recent Results Cancer Res 2014; 201: 269-297.
6. Yun H, Damm F, Yap D, Schwarzer A, Chaturvedi A, Jyotsana N, Lubbert M, Bullinger L, Dohner K, Geffers R, Aparicio S, Humphries RK, Ganser A and Heuser M. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica 2014; 99: 1456-64.
7. Liang W, Shao W, Jiang G, Wang Q, Liu L, Liu D, Wang Z, Zhu Z and He J. Chinese multi-institutional registry (CMIR) for resected non-small cell lung cancer: survival analysis of 5,853 cases. J Thorac Dis 2013; 5: 726-729.
8. Kolligs FT and Graser A. [Early detection of colorectal cancer: role of endoscopy and imaging]. Internist (Berl) 2013; 54: 797-802.
9. Moon JW, Lee SK, Lee JO, Kim N, Lee YW, Kim SJ, Kang HJ, Kim J, Kim HS and Park SH. Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. J Exp Clin Cancer Res 2014; 33: 4.
10. Shark KB and Lee NM. Cloning, sequencing and localization to chromosome 11 of a cDNA encoding a human opioid-binding cell adhesion molecule (OBCAM). Gene 1995; 155: 213-21.
11. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, Brown I, Williams AR, Bates PA, Smyth JF and Gabra H. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34: 337-343.
12. Reed JE, Dunn JR, du Plessis DG, Shaw EJ, Reeves P, Gee AL, Warnke PC, Sellar GC, Moss DJ and Walker C. Expression of cellular adhesion molecule 'OPCML' is down-regulated in gliomas and other brain tumours. Neuropathol Appl Neurobiol 2007; 33: 77-85.
13. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, Loyo M, Chan AT, Srivastava G, Tsao GS, Sellar GC, Sung JJ, Sidransky D and Tao Q. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One 2008; 3: e2990.
14. McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE and Gabra H. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov 2012; 2: 156-171.
15. McNeish IA, Bell SJ and Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 2004; 11: 497-503.
16. Duarte-Pereira S, Paiva F, Costa VL, Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, Ribeiro FR, Silva VM, Oliveira J, Henrique R and Jeronimo C. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer 2011; 47: 1106-1114.
17. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65: 8961-8967.
18. Ye F, Zhang SF, Xie X and Lu WG. OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma. Cancer Invest 2008; 26: 569-574.
19. Chen H, Ye F, Zhang J, Lu W, Cheng Q and Xie X. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. Eur J Gynaecol Oncol 2007; 28: 464-467.
20. Pain M, Bermudez O, Lacoste P, Royer PJ, Botturi K, Tissot A, Brouard S, Eickelberg O and Magnan A. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev 2014; 23: 118-130.
21. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-230.
22. Lee JM, Dedhar S, Kalluri R and Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
23. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH and Robertson KD. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002; 11: 2091-2102.
24. Mei FC, Young TW, Liu J and Cheng X. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J 2006; 20: 497-499.
25. Uzawa K, Suzuki H, Komiya A, Nakanishi H, Ogawara K, Tanzawa H and Sato K. Evidence for two distinct tumor-suppressor gene loci on the long arm of chromosome 11 in human oral cancer. Int J Cancer 1996; 67: 510-514.
26. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM, Lenburg M and Thiagalingam S. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 2010; 70: 968-978.
27. Wang J, Wang Y and Wong C. Oestrogen-related receptor alpha inverse agonist XCT-790 arrests A549 lung cancer cell population growth by inducing mitochondrial reactive oxygen species production. Cell Prolif 2010; 43: 103-113.
28. Lu D, Kiriyama Y, Lee KY and Giguere V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res 2001; 61: 6755-6761.
29. Winczyk K, Pawlikowski M, Guerrero JM and Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 2002; 23: 298-302.
30. Wang Y, Solt LA, Kojetin DJ and Burris TP. Regulation of p53 stability and apoptosis by a ROR agonist. PLoS One 2012; 7: e34921.